What is the latest published ZBH stock rating?

Zimmer Biomet Holdings, Inc. is shown with Strong Buy in the latest published report, analyzed 2026-10-11. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ZBH analysis?

The full latest published report, analyzed 2026-10-11, lives at /stocks/ZBH/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for ZBH?

The latest published report analyzed 2026-10-11 gives ZBH a fair value of USD 120 and a potential value of USD 186. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the ZBH page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-11). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

ZBH Stock: Fundamentals & Analysis | StockMarketAgent.AI

ログイン Start free

Zimmer Biomet Holdings, Inc. (ZBH)

NYSE: ZBH · USD

—

StockMarketAgent Research · Analyzed 2026-10-11

Our latest published analysis: ZBH rated Strong Buy

Zimmer Biomet Holdings, Inc.'s published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$120 / share

Potential value

$186 / share

Upside to FV

+34.2%

Moat

7.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$17.0B
P/E (forward)	10.1x

Market data

Price

Recent price action with selectable time range.

Financial snapshot

P/E (forward): 10.1x
Market cap: $17.0B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$6.83B	$6.94B	$7.39B	$7.68B	$8.23B	+4.8%
Gross profit	$4.87B	$4.92B	$5.31B	$5.49B	$5.07B	+1.0%
Operating income	$860.3M	$696.3M	$1.28B	$1.29B	$1.10B	+6.3%
Net income	$401.6M	$231.4M	$1.02B	$903.8M	$705.1M	+15.1%
EPS (diluted)	$1.91	$1.10	$4.88	$4.43	$3.55	+16.8%
EBITDA	$1.65B	$1.49B	$2.22B	$2.25B	$2.22B	+7.7%
R&D	$435.8M	$406.0M	$458.7M	$437.4M	$458.5M	+1.3%
SG&A	$2.84B	$2.76B	$2.84B	$2.93B	$3.26B	+3.5%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	—	—	—	—	—	—	売り
ABNB	Airbnb, Inc.	—	—	—	—	—	—	売り
ADBE	Adobe Inc.	—	—	—	—	—	—	強い買い
ABBV	AbbVie Inc.	—	—	—	—	—	—	売り
ABT	Abbott Laboratories	—	—	—	—	—	—	縮小
ALGN	Align Technology Inc.	—	—	—	—	—	—	縮小

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($119.59). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.3%	2.5%	2.8%	3.0%
6.4%	$131	$136	$141	$147	$153
6.9%	$122	$125	$129	$133	$138
7.4%	$114	$116	$120	$123	$127
7.9%	$107	$109	$112	$115	$118
8.4%	$101	$103	$105	$108	$110

Scorecard

Published factor rows and weighted composite

Valuation8.5

Management7.5

Balance Sheet7.0

Profitability5.0

Revenue Growth4.5

Risk Assessment7.5

Competitive Moat7.5

Earnings Quality9.0

Capital Efficiency3.5

Weighted composite

6.7/10

Above average

Category	Score	Reading
Valuation	8.5
Management	7.5
Balance Sheet	7.0
Profitability	5.0
Revenue Growth	4.5
Risk Assessment	7.5
Competitive Moat	7.5
Earnings Quality	9.0
Capital Efficiency	3.5

レーティング履歴

各月に公開されたリサーチ版が示したレーティングです。レーティングは分析時点の株価を公正価値と比較したもので、判断が当たったかどうかの記録ではありません。

年	1月	2月	3月	4月	5月	6月	7月	8月	9月	10月	11月	12月
2026

強い買い

Zimmer Biomet Holdings, Inc. (ZBH)

Our latest published analysis: ZBH rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Latest news · ZBH

Valuation

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

Deeper analysis on ZBH

Frequently asked questions

レーティング履歴